{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:54:18Z","timestamp":1787759658104,"version":"build-2784847793"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jacl.2021.05.003","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T12:12:02Z","timestamp":1622117522000},"page":"579-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early use of PCSK9 inhibitor therapy after heart transplantation from a hepatitis C virus positive donor"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2695-5537","authenticated-orcid":false,"given":"Matthew M.","family":"Fanous","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Gianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy L.","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Majure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jacl.2021.05.003_bib0001","first-page":"319","article-title":"Cardiac allograft vasculopathy: a review","volume":"48","author":"Ramzy","year":"2005","journal-title":"Can J Surg"},{"issue":"1","key":"10.1016\/j.jacl.2021.05.003_bib0002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.CIR.0000043241.32523.EE","article-title":"Simvastatin initiated early after heart transplantation: 8-year prospective experience","volume":"107","author":"Wenke","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacl.2021.05.003_bib0003","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction?: a meta-regression analysis","volume":"46","author":"Robinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2021.05.003_bib0004","doi-asserted-by":"crossref","first-page":"e13454","DOI":"10.1111\/ctr.13454","article-title":"Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus","volume":"33","author":"Heeney","year":"2019","journal-title":"Clin Transplant"},{"issue":"10","key":"10.1016\/j.jacl.2021.05.003_bib0005","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2468-1253(19)30240-7","article-title":"Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study","volume":"4","author":"Bethea","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jacl.2021.05.003_bib0006","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.healun.2019.06.023","article-title":"Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era","volume":"38","author":"Madan","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.jacl.2021.05.003_bib0007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","article-title":"Management of dyslipidemia in adult solid organ transplant recipients","volume":"13","author":"Warden","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2021.05.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02142-18","article-title":"Pharmacokinetic interactions between the hepatitis C virus inhibitors elbasvir and grazoprevir and HIV protease inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in healthy volunteers","volume":"63","author":"Feng","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jacl.2021.05.003_bib0009","article-title":"Safety and efficacy of PCSK9 inhibitors after heart transplantation","volume":"35","author":"Moayedi","year":"2019","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2021.05.003_bib0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/pds.3199","article-title":"Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in the health improvement network","volume":"21","author":"Rowan","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"22","key":"10.1016\/j.jacl.2021.05.003_bib0011","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1161\/CIRCULATIONAHA.116.023687","article-title":"Pleiotropic effects of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) inhibitors?","volume":"134","author":"Bittner","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacl.2021.05.003_bib0012","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jacl.2019.06.010","article-title":"PCSK9 inhibition in patients with heart transplantation: a case series","volume":"13","author":"Sandesara","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2021.05.003_bib0013","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jaccas.2019.09.026","article-title":"Use of PCSK9 inhibitors in solid organ transplantation recipients","volume":"2","author":"Warden Bruce","year":"2020","journal-title":"JACC Case Rep"},{"issue":"7","key":"10.1016\/j.jacl.2021.05.003_bib0014","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/01.RES.0000261982.76892.09","article-title":"Vascular remodeling in transplant vasculopathy","volume":"100","author":"Mitchell Richard","year":"2007","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.jacl.2021.05.003_bib0015","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.healun.2014.08.003","article-title":"The registry of the international society for heart and lung transplantation: thirty-first official adult heart transplant report\u20142014; focus theme: retransplantation","volume":"33","author":"Lund","year":"2014","journal-title":"J Heart Lung Transplant"},{"issue":"16","key":"10.1016\/j.jacl.2021.05.003_bib0016","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.107.711911","article-title":"Cardiac allograft vasculopathy","volume":"117","author":"Schmauss","year":"2008","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacl.2021.05.003_bib0017","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/01.RES.0000246086.93555.f3","article-title":"Allograft vasculopathy versus atherosclerosis","volume":"99","author":"Rahmani","year":"2006","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.jacl.2021.05.003_bib0018","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.healun.2019.08.004","article-title":"The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match","volume":"38","author":"Khush","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"10.1016\/j.jacl.2021.05.003_bib0019","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"The international society of heart and lung transplantation guidelines for the care of heart transplant recipients","volume":"29","author":"Costanzo","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.jacl.2021.05.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210373","article-title":"Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation","volume":"14","author":"K\u00fchl","year":"2019","journal-title":"PLoS ONE"},{"issue":"27","key":"10.1016\/j.jacl.2021.05.003_bib0021","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.3748\/wjg.v21.i27.8293","article-title":"Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes","volume":"21","author":"Simon","year":"2015","journal-title":"World J Gastroenterol\u00a0 WJG"},{"issue":"7","key":"10.1016\/j.jacl.2021.05.003_bib0022","first-page":"417","article-title":"Effects of statins on the risk of hepatocellular carcinoma","volume":"10","author":"Mansourian","year":"2014","journal-title":"Gastroenterol Hepatol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742100074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742100074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:35:35Z","timestamp":1761831335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328742100074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S193328742100074X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2021.05.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early use of PCSK9 inhibitor therapy after heart transplantation from a hepatitis C virus positive donor","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2021.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}